Trial reportJournal of child and adolescent psychopharmacology2008
Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.
Trial report in Journal of child and adolescent psychopharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Drugs used in psychiatry causing an increase in body weight in children-a review.International journal of obesity (2005) · 2025Pooled it
- Prolactin-related adverse events and change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A systematic review.BMC pediatrics · 2016Pooled it
- Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.Paediatric drugs · 2013Pooled it
- Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.Indian journal of pharmacologyPooled it
- The Role of Sodium Valproate in Clozapine-Associated Cardiotoxicities: The Importance of Cellular and Systemic Energetics.Cardiovascular toxicology · 2026Review
- Clinical response to clozapine in Black people with psychosis: A secondary analysis of an open-label clinical trial.Therapeutic advances in psychopharmacology · 2026Article
- Efficacy and tolerability of pharmacological interventions for schizophrenia non-responsive to prior treatment: a systematic review and network meta-analysis.EClinicalMedicine · 2025Article
- Lost in Translation: Challenges in the Diagnosis and Treatment of Early-Onset Schizophrenia.Cureus · 2023Review
- Treatment resistant psychosis in children and adolescents and clozapine: Nuances.Frontiers in psychiatry · 2023Review
- Delusional Misidentification Syndromes: Untangling Clinical Quandary With the Newer Evidence-Based Approaches.Cureus · 2021Article
- Interest of Fluvoxamine as an Add-On to Clozapine in Children With Severe Psychiatric Disorder According to CYP Polymorphisms: Experience From a Case Series.Frontiers in psychiatry · 2021Article
- Childhood-onset schizophrenia: what do we really know?Health psychology and behavioral medicine · 2014Article
- Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.The Psychiatric clinics of North America · 2012Review
- Antipsychotic treatment of adolescent dual diagnosis patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2011Article
- Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2011Article
- Pharmacotherapy for treatment-resistant schizophrenia.Neuropsychiatric disease and treatment · 2011Article
- Metabolic Disturbances, Side Effect Profile and Effectiveness of Clozapine in Adolescents.Indian journal of psychological medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveA recent 12-week controlled comparison demonstrated the superiority of clozapine to "high-dose" olanzapine in adolescents with treatment-refractory schizophrenia. In the present study, the authors conducted a 12-week, open-label, follow-up study to examine changes in lipid and glucose metabolism in youths maintained on clozapine and to determine whether patients who were previously randomized to high-dose olanzapine (up to 30 mg/day) responded to clozapine.
methodThirty three (14 clozapine, 19 olanzapine) (85%) of 39 patients were available for the present 12-week, open-label extension study. Extended safety data using an intention-to-treat analysis from the 14 subjects treated with clozapine for a total of 24 weeks are presented. In addition, we report the clinical outcomes for 10 of 19 olanzapine-treated patients who were switched after 12 weeks to clozapine due to treatment nonresponse. Clinical response was defined as a decrease of 30% or more in total Brief Psychiatric Rating score from week 12 and a Clinical Global Impression-Improvement rating of 1 (very much improved) or 2 (much improved).
resultsThe incidence of hypertriglyceridemia (defined as fasting triglycerides >125 mg/dL) (10/14 = 71%) and the incidence of "prediabetes" (defined as fasting blood glucose > or =100) (4/14 = 29%) at week 24 in the clozapine-treated subjects were notable. Seven (70%) of 10 of young patients with schizophrenia who failed treatment with "high-dose" olanzapine were found to respond to a 12-week, open-label clozapine trial.
conclusionsClinicians and caregivers need to be aware of potential metabolic adverse events of long-term clozapine treatment. Adolescents with a poor response to olanzapine may do better on clozapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.